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Summary  
Changes in L-arginine metabolism, including increased arginase levels and decreased 
nitric oxide production, are involved in the pathophysiology of asthma. In this study, 
using an intranasal mite-induced NC/Nga mouse model of asthma, we examined 
whether administration of L-arginine ameliorated airway hyperresponsiveness and 
inflammation by altering L-arginine metabolism. Experimental asthma was induced in 
NC/Nga mice via intranasal administration of mite crude extract (50 μg/day) on 5 
consecutive days (days 0-4, sensitization) and on day 11 (challenge). Oral 
administration of L-arginine (250 mg/kg) was performed twice daily on days 5-10 for 
prevention or on days 11-13 for therapy. On day 14, we evaluated the inflammatory 
airway response (airway hyperresponsiveness, the number of cells in the 
bronchoalveolar lavage fluid, and the changes in pathological inflammation of the lung), 
arginase expression and activity, L-arginine bioavailability, and the concentration of 
NOx, the end products of nitric oxide. Treatment with L-arginine ameliorated the 
mite-induced inflammatory airway response. Furthermore, L-arginine administration 
attenuated the increases in arginase expression and activity and elevated the NOx levels 
by enhancing L-arginine bioavailability. These findings indicate that L-arginine 
administration may contribute to the improvement of asthmatic symptoms by altering 
L-arginine metabolism.   
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Introduction   
    Asthma is a chronic inflammatory disease of the lung that is characterized by 
variable airflow obstruction, airway hyperresponsiveness (AHR), and airway 
inflammation, and frequent and spontaneous exacerbations and remissions.
(1,2)
 Thus, it 
is desirable to effectively prevent these exacerbations and treat prolonged and severe 
asthmatic attacks.  
    Accumulating evidence suggests that changes in L-arginine (Arg) metabolism are 
involved in the pathogenesis of asthma. Arg is catabolized by nitric oxide synthase 
(NOS) and arginase.
(3-5)
 The catabolism of Arg by NOS produces NO and L-citrulline 
(Cit). NO plays an important role in inflammation, host defense, and the regulation of 
the airway bronchomotor and pulmonary vascular tone by inducing the relaxation of 
smooth muscle. Moreover, NO deficiency caused by reduced Arg bioavailability for 
NOS-mediated metabolism is related to the development of asthma.
(3,4,6)
 Arginase is the 
enzyme involved in the urea cycles and consists of the two isoforms І and ІІ. Arginase 
catalyzes Arg hydrolysis into urea and L-ornithine (Orn). The metabolites of Orn, 
polyamine and L-proline, are involved in airway remodeling by promoting cell 
proliferation and collagen synthesis.
(3-5,7)
 Our and other studies have shown an increased 
level of arginase І in an experimental asthma model and in asthmatic patients.(8-11) 
Interestingly, we have demonstrated that the inhibition of arginase attenuated the 
decrease in the concentration of NOx in the asthmatic state and ameliorated airway 
allergic reactions and inflammation.
(12)
 Studies from other groups have also shown that 
the inhibition of arginase alleviates the allergic characteristics of asthma.
(9,13)
 Given 
these findings, it is likely that consumption of Arg by arginase inhibits the production of 
NO by reducing the Arg bioavailability to NOS, thereby contributing to the 
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development of asthma, including AHR, inflammation, and remodeling.  
    It is known that the administration of exogenous Arg elicits an increase in NO 
production, even when excess levels of Arg are available, a circumstance referred to as 
the “Arg paradox”.(14-16) Interestingly, ex vivo treatment with Arg reduced AHR in 
tracheae isolated from ovalbumin-challenged guinea-pigs, an asthma model.
(17,18)
 
Furthermore, in vivo oral administration of Arg alleviated the AHR and airway 
inflammation in an ovalbumin-induced murine model of asthma.
(19)
 Taken together, Arg 
administration may ameliorate airway allergic reactions by modulating Arg metabolism 
via a mechanism that involves arginase, Arg bioavailability, and NO.  
    In this study, using a mite-challenged NC/Nga mouse model,
(8,12,20)
 we addressed 
the preventive or therapeutic effect of Arg administration on the clinical parameters of 
experimental asthma before and after challenge with mites. We also investigated the 
alterations in arginase expression and activity, Arg availability and NOx following Arg 
supplementation.  
 
Materials and Methods 
  Animals.  Male 7-week-old NC/Nga mice were obtained from Charles River 
Laboratories Japan (Yokohama, Japan). The care and handling of the animals were in 
accordance with the Guidelines for the Care and Use of Laboratory Animals at Shikata 
Campus of Okayama University and were approved by the Okayama University 
Institutional Animal Care and Use Committee.  
 
  Induction of asthma and treatment with Arg.  Induction of experimental asthma 
was performed on NC/Nga mice via sensitization and challenge using mite crude extract 
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from Dermatophagoides farinae (Df) (Cosmo Bio, Tokyo, Japan) as previously 
described.
(20,21)
 Briefly, Df crude extract (50 μg/25 μl in saline, Df group) or saline (25μl, 
saline group) was intranasally administered via on 5 consecutive days (day 0-4, 
sensitization) and on day 11 (challenge) under anesthesia. In addition to administrating 
the Df crude extract, Arg (250 mg/kg, dissolved in saline) was orally administered twice 
daily on days 5-10 (Df+Arg-1 group; prevention group) or on days 11-13 (Df+Arg-2 
group; therapy group). The dose of Arg was selected based on a previous study.
(19)
 The 
mice in the Df and saline groups received oral saline alone on the same days. The 
schematic protocol is shown in Fig. 1.  
 
  Assessment of AHR.  On day 14, AHR to acetylcholine was measured as described 
previously.
(12,21)
 Dose-response curves for acetylcholine (from 62.5 to 4,000 μg/kg) in 
anesthetized, mechanically ventilated mice were obtained. Bronchoconstriction was 
expressed as the respiratory overflow volume provoked by acetylcholine as a percentage 
of the maximal overflow volume (100%) obtained by completely occluding the tracheal 
cannula.  
 
  Collection of bronchoalveolar lavage fluid (BALF) and plasma.  Immediately 
after the assessment of acetylcholine-induced AHR, bronchoalveolar lavage was 
performed. BALF samples were processed and used to determine the numbers of total 
cells and of different cell types as described previously.
(12,21)
 Blood samples were 
collected, and plasma was separated for further analysis.  
 
  Preparation of lung specimens.  After the collection of BALF and plasma, lung 
R. Zhang et al., Page 6 
 
tissue was harvested as described previously.
(12,21)
 A portion of the lung tissue was fixed 
in 10% neutral phosphate-buffered formalin for morphological examination. The 
remaining lung tissue was homogenized in buffer containing 20 mM Tris-HCl, pH 7.5, 
150 mM NaCl, and complete protease inhibitor mixture tablets (Roche, Mannheim, 
Germany) with or without 1% Triton X-100. The lung samples treated with 1% Triton 
X-100 were ultracentrifuged, and the supernatants were used for further analysis.  
 
  Histopathological evaluation.  The fixed lung tissues were embedded in paraffin. 
Sections were sliced and stained with hematoxylin and eosin to assess the degree of 
inflammation. The levels of inflammation in the peribronchial and perivascular spaces 
of the lung were determined using an ordinal scale ranging from 0 to 3, as described 
previously.
(21,22)
  
 
  Western blot analysis.  To examine the arginase protein expression level, Western 
blot analysis was performed as described previously.
(12,21)
 Equal amounts of protein 
from the lung tissue samples treated with 1% Triton X-100 or plasma were subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were transferred to a 
polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). These 
membranes were incubated in primary antibodies against arginase I, arginase II (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) or the internal control β-actin (Abcam, 
Cambridge, UK). Corresponding horseradish peroxidase-conjugated secondary 
antibodies were used. Signals were visualized using an enhanced chemiluminescence 
Western blot detection system (Perkin-Elmer, Boston, MA). Each band was quantified 
using Image J software. The expression level of each arginase isoform in the lung tissue 
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was normalized to that of β-actin. The data are expressed as the fold-change in 
expression.  
 
  Measurement of arginase activity.  Arginase activity was measured as described 
previously,
(12,21)
 with minor modifications. Briefly, endogenous urea in the lung samples 
treated with 1% Triton X-100 was removed using an Amicon Ultra-0.5 centrifugal filter 
device (10K molecular weight cutoff; Millipore). The samples were incubated in the 
presence of Arg and MnCl2 at 37ºC for 60 min. The amount of the reaction product urea 
was measured using a urea assay kit (BioChain Institute, Inc., Hayward, CA, USA) 
according to the manufacturer’s instructions.  
 
  Measurement of Arg, Cit, and Orn.  The concentration of Arg, Cit, and Orn in the 
lung samples was quantified via high-performance liquid chromatography followed by 
fluorescence detection as described previously,
(23)
 with minor modifications. Briefly, 10 
μl of the lung sample treated without 1% Triton X-100 was mixed with 50 μl of 1.5 M 
HClO4. After 2 min, 1 ml of H2O, 25 μl of 2 M K2CO3, and 125 μl of 100 μM 
monomethylarginine, an internal standard, were added. This mixture was vortexed and 
centrifuged to obtain the supernatant for analysis. The supernatant was mixed with an 
equal amount of derivatization reagent (1 mg/ml ortho-phthaldialdehyde, 2% methanol, 
and 0.1% 3-mercaptopropionic acid in 200 mM borate buffer, pH 8.5) and was 
equilibrated for 30 min at room temperature. This sample was injected into the 
high-performance liquid chromatography system consisting of a solvent delivery system 
and fluorometer (HITACHI Ltd, Tokyo, Japan). An Ascentis® C18 (15 cm × 4.6 mm, 3 
μm; Supelco Inc., Bellefonte, PA, USA) and an Ascentis® C18 Supelguard™ (2 cm × 
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4.0 mm, 3 μm; Supelco Inc.) were used as the analytical column and the guard column, 
respectively. Mobile phase A consisted of 0.1 M sodium acetate, pH 7.2, containing 9% 
methanol and 0.5% tetrahydrofuran, and mobile phase B was 100% methanol. The 
following elution conditions were used: flow rate of 1.1 ml/min; column temperature of 
30ºC; 0-15 min, isocratic elution using 91% mobile phase A and 9% mobile phase B; 
15-20 min, linear gradient to 70% mobile phase A and 30% mobile phase B; 20-30 min, 
linear gradient to 65% mobile phase A and 35% mobile phase B; 30-35 min, isocratic 
elution using 65% mobile phase A and 35% mobile phase B; 35-38 min, linear gradient 
to 50% mobile phase A and 50% mobile phase B; and 38-50 min, linear gradient to 45% 
mobile phase A and 55% mobile phase B. The total run time was 60 min including the 
time for column regeneration: 51-54 min, isocratic elution using 100% mobile phase B; 
54.1-60 min, isocratic elution using 91% mobile phase A and 9% mobile phase B. The 
fluorescence excitation and emission wavelengths were 340 and 455 nm, respectively. 
 
  Measurement of the NOx concentrations.  To estimate NO production in the lung, 
the concentration of NOx, consisting of nitrite (NO2
-
) and nitrate (NO3
-
), was 
determined using a NO analyzer (Model-280i NOA with a Purge Vessel; Sievers, 
Boulder, CO) as described previously.
(12,21)
 Briefly, the lung sample treated without 1% 
Triton X-100 was treated with nitrate reductase (Sigma, St. Louis, MO, USA) to convert 
NO3
-
 to NO2
-
 at room temperature for 30 min. After removing proteins via precipitation 
with acetonitrile, NO2
-
 in the supernatant was further reduced to NO in a Purge Vessel 
containing the reducing agent potassium iodide in acetic acid. Subsequently, NO was 
detected using the ozone-chemiluminescence method.  
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  Statistical analysis.  All results are expressed as the means ± SEM. If the difference 
based on via one-way or two-way analysis of variance (ANOVA) was significant, 
Bonferroni’s post hoc test or Tukey’s multiple comparison test was used for paired 
comparisons using GraphPad Prism for Windows (GraphPad Software, Inc., San Diego, 
CA, USA). The results were considered to be significantly different at P < 0.05.   
 
Results   
  Effect of Arg on AHR to acetylcholine.  We measured AHR to acetylcholine. 
Compared with the saline group, a significant increase in AHR in response to 
acetylcholine was found in the Df group. However, remarkably attenuated AHR were 
observed in the Df+Arg-1 and the Df+Arg-2 groups compared to the Df group (Fig. 2).  
 
  Effect of Arg on the cell counts in the BALF.  We examined the accumulation of 
inflammatory cells in the BALF. The numbers of inflammatory cells, including total 
cells, lymphocytes, macrophages, and eosinophils, in BALF were significantly 
increased in the Df group than in the saline group. However, significant decreased 
numbers of inflammatory cells in the BALF were detected in the Df+Arg-1 and the 
Df+Arg-2 groups than in the Df group (Fig. 3A-D).  
 
  Effect of Arg on the scores of lung inflammation.  We investigated the 
histopathological changes in the lung. Compared with the saline group, significantly 
higher inflammation scores in the perivascular area and the peribronchial space were 
found in the Df group. However, inflammation scores in the Df+Arg-1 and the 
Df+Arg-2 group were significant lower than those of the Df group (Fig. 4A-E).  
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  Effect of Arg on the protein expression and activity of arginase.  We assessed the 
protein expression and activity of arginase. Quantitative Western blot analysis revealed 
higher expression of arginase І and arginase ІІ in the lung tissue from the Df group than 
that from the saline group. Interestingly, treatment with Arg significantly attenuated the 
mite-induced expression of arginase І, although no significant difference in the 
expression of arginase ІІ was detected between the Df group and either the Df+Arg-1 or 
Df+Arg-2 group (Fig. 5A). The increased activity of arginase in the lung from the Df 
group was significantly attenuated in that from the Df+Arg-1 and Df+Arg-2 groups (Fig. 
5B). In addition, interestingly, arginase І expression in plasma was higher in the Df 
group than in the saline group. Importantly, the mite-induced expression of arginase І in 
plasma was significantly attenuated by the administration of Arg (Fig. 6). These data 
suggest that Arg supplementation attenuated the increases in the expression and activity 
of arginase І in mite-induced asthma.  
 
  Effect of Arg on Arg bioavailability and the NOx levels.  We evaluated the Arg 
bioavailability ratio for cellular utilization, characterized by the ratio of Arg to Orn plus 
Cit, which are products generated from the enzymatic catabolism of Arg,
(24,25)
 and the 
NOx concentration in the lung tissue. No significantly difference in the concentration of 
Arg was detected between the groups (Fig. 7A). However, the Arg availability ratio, 
Arg/(Orn+Cit), was slightly higher in the Df+Arg-1 (P =0.015) and Df+Arg-2 (P 
=0.081) groups than in the Df group (Fig. 7B). The concentration of NOx was 
significantly higher in the Df+Arg-2 group than in the other groups (Fig. 7C). These 
results suggest that Arg administration increases the production of NO by enhancing 
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Arg bioavailability.  
 
Discussion   
    The data from this study demonstrate that, in terms of asthma prevention and 
therapy, Arg administration ameliorated AHR and inflammation in a mite-induced 
NC/Nga mouse model of asthma. We also found that treatment with Arg attenuated the 
increases in the protein expression and activity of arginase and induced changes in Arg 
metabolism, including the enhancement of Arg bioavailability and the increase in the 
concentration of NOx.  
    In this study, we used an experimental asthmatic model of NC/Nga mice subjected 
to intranasal administration of mite allergen, a common allergen, without adjuvant. This 
model is considered to closely resemble human asthma.
(20)
 Our previous studies using 
this model have demonstrated that increased levels of arginase І and concomitantly 
decreased production of NO may be implicated in the development of asthma.
(8,12,21)
  
    We found that Arg administration ameliorated the pathophysiologic allergic 
changes induced by mites, as demonstrated by the amelioration of AHR, the decrease in 
the number of inflammatory cells in the BALF, and the reduction in inflammation in the 
lung tissue. We also found that Arg administration attenuated the increase in the mRNA 
expression of Th2-related cytokines, such as inteleukin-4 and inteleukin-5, in the 
asthmatic lung (unpublished data). Furthermore, the increased expression and activity of 
arginase in the mite-induced asthmatic lung tissue and plasma were attenuated by Arg 
supplementation. Given that arginase contributes to the pathophysiology of asthma, 
(7,9,12,13)
 we propose that this Arg administration-mediated decrease in the expression and 
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activity of arginase might be responsible for the amelioration of pathophysiologic 
allergic reactions in asthma.  
    Arg supplementation was performed before or after mite challenge because we 
aimed to assess its preventive and therapeutic effects, respectively. The therapeutic 
administration of Arg (Df+Arg-2 group) resulted in the enhancement of Arg 
bioavailability and the increase in the NOx levels. Considering that Arg is catabolized 
by both arginase and NOS as a substrate,
(3-5)
 increased Arg bioavailability may be, at 
least in part, due to the decreased levels of arginase. Furthermore, no change in the 
mRNA expression of NOS2 was detected in the lung tissue from the asthmatic or 
Arg-administered asthmatic mice compared to that from the saline-treated mice 
(unpublished data). Collectively, we propose that the restoration of Arg bioavailability 
to NOS, independently of NOS expression, by Arg administration may improve 
asthmatic symptoms via increased NO production.   
   Similar to therapeutic Arg administration, preventive therapeutic administration of 
Arg (Df+Arg-1 group) resulted in attenuated levels of arginase, enhanced Arg 
bioavailability, and ameliorated asthmatic symptoms, although no change in the NOx 
levels was detected. This finding regarding the NOx levels may be due to timing of Arg 
administration (on days 5-10) and sample collection (day 14). Given the “Arg paradox”, 
in which acute exogenous administration of Arg increases NO production despite 
apparently saturating the intracellular level of the substrate,
(14-16)
 the NOx levels may be 
increased by enhancing Arg bioavailability to NOS, independently of NOS expression, 
during the preventive administration of Arg (on days 5-10) and surrounding 
mite-challenge (on day 11). Therefore, we speculate that the increased level of NO 
mediated by preventive treatment with Arg may partially ameliorate airway allergic 
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reactions and inflammation, although we did not examine in this hypothesis in detail.  
    The mechanism by which Arg supplementation decreases the expression of 
arginase І remains unclear. The expression of arginase І is regulated by various stimuli, 
including Th2-related cytokines, such as inteleukin-4, growth factors, oxygen tension, 
and reactive oxygen species (ROS).
(3,7)
 The upregulation of arginase І by Th2-related 
cytokines is regulated by the transcription factors CCAAT-enhancer binding protein and 
STAT6.
(26)
 Thus, it is likely that the attenuated levels of Th2-related cytokines caused by 
Arg administration accounts for the decreased expression of arginase І. Alternatively, 
our population studies have shown that induction of arginase І expression was 
associated with increased oxidative stress.
(27-29)
 Oxidative stress is involved in the 
pathophysiology of asthma. Overproduction of ROS activates redox-sensitive 
transcription factors, such as nuclear factor-κB and activator protein-1, and induces the 
expression of pro-inflammatory genes.
(30,31)
 Considering that NO attenuates oxidative 
stress by counteracting ROS, the decreased expression of arginase may be attributed to 
the changes in the redox regulation of transcription via increased NO production. 
Therefore, further studies should elucidate the exact mechanisms by which Arg 
administration regulates the expression of arginase.  
    This study clearly showed that Arg administration alleviated asthmatic symptoms. 
These findings were consistent with a study indicating the beneficial effect of Arg 
administration at the same dose (250 mg/kg) in an ovalbumin-induced murine model of 
asthma,
(19)
 although there was a difference in the timing of Arg administration. 
Conversely, it has been reported that Arg administration potentiated airway 
inflammation in an ovalbumin-induced murine model of asthma;
(32)
 however, there was 
a difference in the dose (12.5 mg/kg) of Arg administered.  
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    In conclusion, the present study proposes that Arg administration may be useful for 
the prevention or treatment of asthma by attenuating the expression and activity of 
arginase and by modulating the metabolism of Arg. Further studies are required to 
elucidate the precise mechanisms by which Arg supplementation ameliorates asthmatic 
symptoms, modulates arginase expression and activity, and alters Arg metabolism.  
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Figure Legends 
Fig. 1.    Schematic illustration of the experiment.  
 
Fig. 2.    The effect of Arg on AHR to acetylcholine in mite-induced asthma. 
Two-way ANOVA revealed a significant effect of the acetylcholine dose, P < 0.0001; 
group, P < 0.0001; acetylcholine dose  group, P < 0.0001. *P < 0.05, **P < 0.01, and 
***P < 0.001 vs. the Df group based on one-way ANOVA followed by Bonferroni’s 
post hoc test after confirming an interaction between the acetylcholine dose and the 
groups via two-way ANOVA (n = 5 to 8 mice/group).  
 
Fig. 3.    The effect of Arg on BALF cell numbers in mite-induced asthma. The 
numbers of total cell (A) lymphocyte (B), macrophage (C), and eosinophil (D) in the 
BALF are shown. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the Df group based on 
one-way ANOVA followed by Tukey’s multiple comparison test (n = 5 to 8 
mice/group).  
 
Fig. 4.    The effect of Arg on histopathological inflammation in the mite-induced 
asthmatic lung. Representative images of hematoxylin and eosin-stained lung tissue 
from the saline (A), Df (B), Df+Arg1 (C), and Df+Arg2 groups (D), and inflammation 
scores (E) are shown. The bars indicate 50 μm. ***P < 0.001 vs. the Df group based on 
one-way ANOVA followed by Tukey’s multiple comparison test (n = 8 mice/group).  
 
Fig. 5    The effect of Arg on the protein expression and activity of arginase in the 
mite-induced asthmatic lung. Representative images and quantification after 
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normalization to β-actin of Western blots for arginase І and arginase ІІ (A), and the 
activity of arginase (B) in the lung tissue are shown. *P < 0.05, **P < 0.01, and ***P < 
0.001 vs. the Df group based on one-way ANOVA followed by Tukey’s multiple 
comparison test (n = 7 to 8 mice/group).  
 
Fig. 6.    The effect of Arg on the protein expression of plasma arginase І in 
mite-induced asthma. Representative images and quantification of Western blots for 
arginase І in plasma are shown. *P < 0.05, and **P < 0.01 vs. the Df group based on 
one-way ANOVA followed by Tukey’s multiple comparison test (n = 6 to 8 
mice/group). 
 
Fig. 7.    The effect of Arg on Arg bioavailability and the NOx levels in the 
mite-induced asthmatic lung. The concentration of Arg (A), the Arg bioavailability ratio, 
expressed as Arg/Orn+Cit (B), and the concentrations of NOx (C) are shown. *P < 0.05 
and **P < 0.01 vs. the Df group based on one-way ANOVA followed by Tukey’s 
multiple comparison test (n = 5 to 8 mice/group).  
 
